Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 257

1.

Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.

Spear S, Candido JB, McDermott JR, Ghirelli C, Maniati E, Beers SA, Balkwill FR, Kocher HM, Capasso M.

Front Immunol. 2019 Mar 27;10:542. doi: 10.3389/fimmu.2019.00542. eCollection 2019.

2.

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC Jr, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ Jr, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L.

Cancer. 2019 Jun 15;125(12):1963-1972. doi: 10.1002/cncr.32004. Epub 2019 Mar 5.

PMID:
30835824
3.

Mets and NETs: The Awakening Force.

Sanz-Moreno V, Balkwill FR.

Immunity. 2018 Nov 20;49(5):798-800. doi: 10.1016/j.immuni.2018.11.009.

PMID:
30462996
4.

CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype.

Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI, Wilkinson RW, Biankin AV, Barry ST, Balkwill FR, Sansom OJ.

Cell Rep. 2018 May 1;23(5):1448-1460. doi: 10.1016/j.celrep.2018.03.131.

5.

Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers.

Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Böhm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, Montfort A, Dowe T, Gribben J, Jones JL, Kocher HM, Serody JS, Vincent BG, Connelly J, Brenton JD, Chelala C, Cutillas PR, Lockley M, Bessant C, Knight MM, Balkwill FR.

Cancer Discov. 2018 Mar;8(3):304-319. doi: 10.1158/2159-8290.CD-17-0284. Epub 2017 Dec 1.

6.

A guiding map for inflammation.

Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, Hotchkiss R, Joosten LAB, Kastner DL, Korte M, Latz E, Libby P, Mandrup-Poulsen T, Mantovani A, Mills KHG, Nowak KL, O'Neill LA, Pickkers P, van der Poll T, Ridker PM, Schalkwijk J, Schwartz DA, Siegmund B, Steer CJ, Tilg H, van der Meer JWM, van de Veerdonk FL, Dinarello CA.

Nat Immunol. 2017 Jul 19;18(8):826-831. doi: 10.1038/ni.3790.

7.

Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.

Naba A, Pearce OMT, Del Rosario A, Ma D, Ding H, Rajeeve V, Cutillas PR, Balkwill FR, Hynes RO.

J Proteome Res. 2017 Aug 4;16(8):3083-3091. doi: 10.1021/acs.jproteome.7b00191. Epub 2017 Jul 19.

PMID:
28675934
8.

A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR.

J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30.

9.

CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Walton J, Blagih J, Ennis D, Leung E, Dowson S, Farquharson M, Tookman LA, Orange C, Athineos D, Mason S, Stevenson D, Blyth K, Strathdee D, Balkwill FR, Vousden K, Lockley M, McNeish IA.

Cancer Res. 2016 Oct 15;76(20):6118-6129. Epub 2016 Aug 16.

10.

A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.

Montfort A, Pearce O, Maniati E, Vincent BG, Bixby L, Böhm S, Dowe T, Wilkes EH, Chakravarty P, Thompson R, Topping J, Cutillas PR, Lockley M, Serody JS, Capasso M, Balkwill FR.

Clin Cancer Res. 2017 Jan 1;23(1):250-262. doi: 10.1158/1078-0432.CCR-16-0081. Epub 2016 Jun 27.

11.

Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.

Böhm S, Montfort A, Pearce OM, Topping J, Chakravarty P, Everitt GL, Clear A, McDermott JR, Ennis D, Dowe T, Fitzpatrick A, Brockbank EC, Lawrence AC, Jeyarajah A, Faruqi AZ, McNeish IA, Singh N, Lockley M, Balkwill FR.

Clin Cancer Res. 2016 Jun 15;22(12):3025-36. doi: 10.1158/1078-0432.CCR-15-2657.

12.

Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma.

Dawkins JB, Wang J, Maniati E, Heward JA, Koniali L, Kocher HM, Martin SA, Chelala C, Balkwill FR, Fitzgibbon J, Grose RP.

Cancer Res. 2016 Aug 15;76(16):4861-71. doi: 10.1158/0008-5472.CAN-16-0481. Epub 2016 Jun 8.

13.

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.

Steele CW, Karim SA, Leach JDG, Bailey P, Upstill-Goddard R, Rishi L, Foth M, Bryson S, McDaid K, Wilson Z, Eberlein C, Candido JB, Clarke M, Nixon C, Connelly J, Jamieson N, Carter CR, Balkwill F, Chang DK, Evans TRJ, Strathdee D, Biankin AV, Nibbs RJB, Barry ST, Sansom OJ, Morton JP.

Cancer Cell. 2016 Jun 13;29(6):832-845. doi: 10.1016/j.ccell.2016.04.014. Epub 2016 Jun 2.

14.

Experimental validation of a flat punch indentation methodology calibrated against unconfined compression tests for determination of soft tissue biomechanics.

Delaine-Smith RM, Burney S, Balkwill FR, Knight MM.

J Mech Behav Biomed Mater. 2016 Jul;60:401-415. doi: 10.1016/j.jmbbm.2016.02.019. Epub 2016 Feb 17.

15.

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells.

Kulbe H, Iorio F, Chakravarty P, Milagre CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D, Braicu I, Sehouli J, Saez-Rodriguez J, Cutillas PR, Balkwill FR.

Oncotarget. 2016 Mar 29;7(13):15648-61. doi: 10.18632/oncotarget.7255.

16.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ Jr, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR.

Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Review.

17.

Centre of the Cell: Science Comes to Life.

Balkwill F, Chambers K.

PLoS Biol. 2015 Sep 4;13(9):e1002240. doi: 10.1371/journal.pbio.1002240. eCollection 2015.

18.

Inflammation and cancer: advances and new agents.

Crusz SM, Balkwill FR.

Nat Rev Clin Oncol. 2015 Oct;12(10):584-96. doi: 10.1038/nrclinonc.2015.105. Epub 2015 Jun 30. Review.

PMID:
26122183
19.

Interleukin-6 Stimulates Defective Angiogenesis.

Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR, Balkwill F.

Cancer Res. 2015 Aug 1;75(15):3098-107. doi: 10.1158/0008-5472.CAN-15-1227. Epub 2015 Jun 16.

20.

Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.

Milagre CS, Gopinathan G, Everitt G, Thompson RG, Kulbe H, Zhong H, Hollingsworth RE, Grose R, Bowtell DD, Hochhauser D, Balkwill FR.

Cancer Res. 2015 Apr 1;75(7):1255-64. doi: 10.1158/0008-5472.CAN-14-1801. Epub 2015 Feb 10.

21.

Murine CD27(-) Vγ6(+) γδ T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages.

Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR, Kulbe H, Pennington DJ, Silva-Santos B.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):E3562-70. doi: 10.1073/pnas.1403424111. Epub 2014 Aug 11.

22.

Chemotherapy, immunity and microbiota--a new triumvirate?

Karin M, Jobin C, Balkwill F.

Nat Med. 2014 Feb;20(2):126-7. doi: 10.1038/nm.3473. No abstract available.

23.

Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts.

Lau TS, Chung TK, Cheung TH, Chan LK, Cheung LW, Yim SF, Siu NS, Lo KW, Yu MM, Kulbe H, Balkwill FR, Kwong J.

J Pathol. 2014 Jan;232(1):43-56. doi: 10.1002/path.4258.

PMID:
24014111
24.

Vaccinia virus induces programmed necrosis in ovarian cancer cells.

Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Öberg D, McNeish IA.

Mol Ther. 2013 Nov;21(11):2074-86. doi: 10.1038/mt.2013.195. Epub 2013 Sep 24.

25.

Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.

Leinster DA, Colom B, Whiteford JR, Ennis DP, Lockley M, McNeish IA, Aurrand-Lions M, Chavakis T, Imhof BA, Balkwill FR, Nourshargh S.

FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.

26.

The tumor microenvironment at a glance.

Balkwill FR, Capasso M, Hagemann T.

J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. doi: 10.1242/jcs.116392. No abstract available.

27.

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

Sandhu SK, Papadopoulos K, Fong PC, Patnaik A, Messiou C, Olmos D, Wang G, Tromp BJ, Puchalski TA, Balkwill F, Berns B, Seetharam S, de Bono JS, Tolcher AW.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50. doi: 10.1007/s00280-013-2099-8. Epub 2013 Feb 6.

PMID:
23385782
28.

B regulatory cells in cancer.

Balkwill F, Montfort A, Capasso M.

Trends Immunol. 2013 Apr;34(4):169-73. doi: 10.1016/j.it.2012.10.007. Epub 2012 Dec 1. Review.

PMID:
23206438
29.

Paraneoplastic thrombocytosis in ovarian cancer.

Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, Chiu W, Lopez-Berestein G, Afshar-Kharghan V, Sood AK.

N Engl J Med. 2012 Feb 16;366(7):610-8. doi: 10.1056/NEJMoa1110352. Erratum in: N Engl J Med. 2012 Nov;367(18):1768. Lamkin, Donald [added].

30.

The peritoneal tumour microenvironment of high-grade serous ovarian cancer.

Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, Cooper D, Gould D, Ennis DP, Lockley M, McNeish IA, Nourshargh S, Balkwill FR.

J Pathol. 2012 Jun;227(2):136-45. doi: 10.1002/path.4002. Epub 2012 Apr 18.

31.

Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.

Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA, Deen S, Brenton JD, Young BD, Balkwill F.

Oncogene. 2012 Nov 29;31(48):4987-95. doi: 10.1038/onc.2011.653. Epub 2012 Jan 23.

32.

Cancer-related inflammation: common themes and therapeutic opportunities.

Balkwill FR, Mantovani A.

Semin Cancer Biol. 2012 Feb;22(1):33-40. doi: 10.1016/j.semcancer.2011.12.005. Epub 2011 Dec 24. Review.

PMID:
22210179
33.

A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment.

Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, Galletta L; Australian Ovarian Cancer Study Group, Salako MA, Smyth JF, Hagemann T, Brennan DJ, Bowtell DD, Balkwill FR.

Cancer Res. 2012 Jan 1;72(1):66-75. doi: 10.1158/0008-5472.CAN-11-2178. Epub 2011 Nov 7.

34.

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, Nedospasov SA, Balkwill FR, Tuveson DA, Hagemann T.

J Clin Invest. 2011 Dec;121(12):4685-99. doi: 10.1172/JCI45797. Epub 2011 Nov 7.

35.

The chemokine system and cancer.

Balkwill FR.

J Pathol. 2012 Jan;226(2):148-57. doi: 10.1002/path.3029. Epub 2011 Nov 23. Review.

PMID:
21989643
36.

Rethinking ovarian cancer: recommendations for improving outcomes.

Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR.

Nat Rev Cancer. 2011 Sep 23;11(10):719-25. doi: 10.1038/nrc3144.

37.

Interleukin-6 as a therapeutic target in human ovarian cancer.

Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

Clin Cancer Res. 2011 Sep 15;17(18):6083-96. doi: 10.1158/1078-0432.CCR-11-0945. Epub 2011 Jul 27.

38.

Safety of medicines and the use of animals in research.

Balkwill F, Whitehead S, Willis P, Gaymond N, Kent A, Page C, Lovell-Badge R, Morris R, Lemon R, Banks D.

Lancet. 2011 Jul 9;378(9786):127-8. doi: 10.1016/S0140-6736(11)60984-7. Epub 2011 Jun 28. No abstract available.

PMID:
21719093
39.

B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR.

Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10662-7. doi: 10.1073/pnas.1100994108. Epub 2011 Jun 13.

40.

Translating science in more ways than one: an interview with Frances Balkwill.

Balkwill F.

Dis Model Mech. 2011 May;4(3):286-8. doi: 10.1242/dmm.007898. No abstract available.

41.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

42.

TNF: a tumor-suppressing factor or a tumor-promoting factor?

Balkwill F, Joffroy C.

Future Oncol. 2010 Dec;6(12):1833-6. doi: 10.2217/fon.10.155.

PMID:
21142857
43.

Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.

Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA.

Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.

44.

p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.

Flak MB, Connell CM, Chelala C, Archibald K, Salako MA, Pirlo KJ, Lockley M, Wheatley SP, Balkwill FR, McNeish IA.

Mol Cancer. 2010 Jul 3;9:175. doi: 10.1186/1476-4598-9-175.

45.

Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.

Toulza F, Nosaka K, Tanaka Y, Schioppa T, Balkwill F, Taylor GP, Bangham CR.

J Immunol. 2010 Jul 1;185(1):183-9. doi: 10.4049/jimmunol.0903846. Epub 2010 Jun 4.

46.

Guidelines for the welfare and use of animals in cancer research.

Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA; Committee of the National Cancer Research Institute.

Br J Cancer. 2010 May 25;102(11):1555-77. doi: 10.1038/sj.bjc.6605642.

47.

Cancer and inflammation: implications for pharmacology and therapeutics.

Balkwill F, Mantovani A.

Clin Pharmacol Ther. 2010 Apr;87(4):401-6. doi: 10.1038/clpt.2009.312. Epub 2010 Mar 3. Review.

PMID:
20200512
48.

Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.

Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V, Novelli M, Balkwill F, Fitzgerald RC.

Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2177-82. doi: 10.1073/pnas.0909797107. Epub 2010 Jan 13.

49.

Foreword.

Balkwill F, Mantovani A.

Cytokine Growth Factor Rev. 2010 Feb;21(1):1. doi: 10.1016/j.cytogfr.2009.11.004. Epub 2010 Jan 19. No abstract available.

PMID:
20034839
50.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann T.

J Clin Invest. 2009 Oct;119(10):3011-23. doi: 10.1172/JCI39065. Epub 2009 Sep 8.

Supplemental Content

Loading ...
Support Center